Ionis reports third quarter 2026 results and progress on key programs
FROM THE WIRE · BUSINESSWIRE.COM
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continue to advance innovative medicines for people with serious…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralQuarterly results from a large biotech with 2026 approvals, relevant for the stock but with no figures in the text.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Ionis cites three approvals of first-in-class medicines in 2026, two of which are Ionis-owned.
- 02CEO Brett P. Monia described the first launch of TRYNGOLZA in a large indication.
- 03The release covers the quarter ended September 30, 2026.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets